361 Capital’s Voyager Therapeutics VYGR Stock Holding History

361 Capital’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-120,143	Closed	-$2.07M	–	404
2019 Q3	$2.07M	Buy	+120,143	New	+$2.52M	0.38%	145
2018 Q3	–	Sell	-83,006	Closed	-$1.62M	–	400
2018 Q2	$1.62M	Buy	+83,006	New	+$1.64M	0.37%	136

Other funds holding VYGR

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

361 Capital's VYGR Position: Q4 2019 in Review

361 Capital sold out of Voyager Therapeutics (VYGR) in Q4 2019, closing a stake of 120,143 shares — an estimated $2.07M sold.

361 Capital first reported a position in VYGR in Q2 2018 and held it in 2 quarters. The position peaked at $2.07M in Q3 2019. 138 funds tracked by Wall St. Rank hold VYGR as of Q4 2019.

361 Capital reported no remaining Voyager Therapeutics position as of Q4 2019 after selling out during the quarter.
361 Capital sold 120,143 Voyager Therapeutics shares in Q4 2019, an estimated $2.07M.
361 Capital first reported a position in Voyager Therapeutics in Q2 2018 and held it in 2 quarters.
361 Capital's Voyager Therapeutics position peaked at $2.07M in Q3 2019.
138 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2019.

Based on 361 Capital's 13F filing for Q4 2019, filed 13 Feb 2020.